[18]   Yu, M., Cambj-Sapunar, L., Kehl, F., Maier, K.G., Takeuchi, K., Miyata, N., et al. (2004) Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. European Journal of Pharmacology, 486, 297-306.

[19]   Gebremedhin, D., Lange, A.R., Lowry, T.F., Taheri, M.R., Birks, E.K., Hudetz, A.G., et al. (2000) Production of 20-HETE and its role in autoregulation of cerebral blood flow Circulation Research, 87, 60-65.

[20]   Omura, T., Tanaka, Y., Miyata, N., Koizumi, C., Sakurai, T., Fukasawa, M., et al. (2006) Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke, 37, 1307-1313.

[21]   Cao, S., Wang, L.C., Kwansa, H., Roman, R.J., Harder, D.R. and Koehler, R.C. (2009) Endothelin rather than 20-HETE contributes to loss of pial arteriolar dilation during focal cerebral ischemia with and without polymeric hemoglobin transfusion. American Journal of Regulatory, Integrative and Comparative Physiology, 296, R1412-R1418. http://dx.doi.org/10.1152/ajpregu.00003.2009

[22]   Liu, X., Li, C., Gebremedhin, D., Hwang, S.H., Hammock, B.D., Falck, J.R., Roman, R.J., Harder, D.R. and Koehler, R.C. (2011) Epoxyeicosatrienoic acid-dependent cerebral vasodilation evoked by metabotropic glutamate receptor activation in vivo. American Journal of Physiol- ogy Heart and Circulation Physiology, 301, H373-H381.

[23]   Qin, X., Kwansa, H., Bucci, E., Roman, R.J. and Koehler, R.C. (2006) Role of 20-HETE in the pial arteriolar constrictor response to decreased hematocrit after exchange transfusion of cell-free polymeric hemoglobin. Journal of Applied Physiology, 100, 336-342.

[24]   Stirone, C., Boroujerdi, A., Duckles, S.P. and Krause, D.N. (2005) Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: Rapid and long-term effects. Molecular Pharmacology, 67, 105-113.

[25]   Razmara, A., Sunday, L., Stirone, C., Wang, X.B., Krause, D.N. and Duckles, S.P., et al. (2008) Mitochondrial effects of estrogen are mediated by estrogen receptor alpha in brain endothelial cells. Journal of Pharmacology and Experimental Theraputics, 325, 782-790.

[26]   Silbergeld, D.L. and Ali-Osman, F. (1991) Isolation and characterization of microvessels from normal brain and brain tumors. Journal of Neuro-Oncology, 11, 49-55.

[27]   Welschen, R., Osman, P., Dullaart, J., de Greef, W.J., Uilenbroek, J.T. and de Jong, F.H. (1975) Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat. Journal of Endocrinology, 64, 37-47.

[28]   Bohacek, J., Bearl, A.M. and Daniel, J.M. (2008) Long-term ovarian hormone deprivation alters the ability of subsequent oestradiol replacement to regulate choline acetyltransferase protein levels in the hippocampus and prefrontal cortex of middle-aged rats. Journal of Neuroendocrinology, 20, 1023-1027.

[29]   Pinna, C., Cignarella, A., Sanvito, P., Pelosi, V. and Bolego, C. (2008) Prolonged ovarian hormone deprivation impairs the protective vascular actions of estrogen receptor alpha agonists. Hypertension, 51, 1210-1217.

[30]   Pelligrino, D.A., Ye, S., Tan, F., Santizo, R.A., Feinstein, D.L. and Wang, Q. (2000) Nitric-oxide-dependent pial arteriolar dilation in the female rat: Effects of chronic estrogen depletion and repletion. Biochemical and Biophysical Research Communications, 269, 165-171.

[31]   Krause, D.N., Duckles, S.P. and Pelligrino, D.A. (2006) Influence of sex steroid hormones on cerebrovascular function. Journal of Applied Physiology, 101, 1252-1261.

[32]   Fisher, M. (2008) Injuries to the vascular endothelium: Vascular wall and endothelial dysfunction. Review of Neurolological Diseases, 5, S4-S11.

[33]   Moien-Afshari, F., Kenyon, E., Choy, J.C., Battistini, B., McManus, B.M. and Laher, I. (2003) Long-term effects of ovariectomy and estrogen replacement treatment on endothelial function in mature rats. Maturitas, 45, 213-223. http://dx.doi.org/10.1016/S0378-5122(03)00149-X

[34]   Imig, J.D., Simpkins, A.N., Renic, M. and Harder, D.R. (2011) Cytochrome P450 eicosanoids and cerebral vascular function. Expert Reviews in Molecular Medicine, 13, e7.

[35]   Toth, P., Csiszar, A., Sosnowska, D., Tucsek, D., Cseplo, P., Springo, Z., et al. (2013) Treatment with cytochrome P450 ω-hydrolase inhibitor HET0016 attenuates cerebro-vascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats. British Journal of Pharmacology, 168, 1878-1888.

[36]   Wang, J.S., Singh, H., Zhang, F., Ishizuka, T., Deng, H., Kemp, R., et al. (2006) Endothelial dysfunction and hypertension in rats transduced with CYP4A2 adenovirus. Circulation Research, 98, 962-969.

[37]   Singh, H., Cheng, J., Deng, H., Kemp, R., Ishizuka, T., Nasjletti, A., et al. (2007) Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension, 50, 123-129.

[38]   Fang, X., Faraci, F.M., Kaduce, T.L., Harmon, S., Modrick, M.L., Hu, S., et al. (2006) 20-hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: Role of cyclooxygenase. American Journal of Physiology Heart and Circulation Physiology, 291, H2301-H2307.